Hiroyuki Uchida, MD, PhD

  • 20Articles
  • 94.8KReads
  • 2008–2025Active
  • 88Collaborators
  • 313Citations

About

Hiroyuki Uchida, MD, PhD, is affiliated with the Department of Neuropsychiatry at Keio University School of Medicine in Tokyo, Japan. Since 2008, Uchida has published extensively on topics including schizophrenia, schizoaffective disorders, bipolar disorder, depression, delirium, dementia, Alzheimer disease, neurology, and cardiology. His work covers clinical pharmacology, dosing strategies, receptor occupancy, and placebo effects in psychiatric and neurodegenerative conditions. Frequent collaborators include Takefumi Suzuki, Masaru Mimura, Hiroyoshi Takeuchi, David C. Mamo, and Gary Remington.

Publications

JCP
IV Hydroxyzine vs Haloperidol for Delirium
Original Research

IV Hydroxyzine vs Haloperidol for Delirium

January 6, 2025

Hydroxyzine showed a significantly higher rate of delirium improvement than haloperidol, with no significant difference in the time to improvement.
, , , et al
JCP
Original Research

Psychiatric Disorders in Patients with PE and AMI

November 9, 2021

This study compared proportions of patients with comorbid psychiatric disorders among those hospitalized for either pulmonary embolism, a common cause of sudden cardiac arrest in psychiatric patients, or acute...
, , , et al
JCP
Meta-Analysis

Single vs Multiple Dose Regimens of Psychotropic Drugs

February 23, 2021

Single-daily-dose regimens are easier for patients to follow than multiple-dose regimens and may increase adherence. But do they work as well? And are they safe? Read this meta-analysis to...
, , , et al
JCP
Original Research

Effects of LAI Paliperidone Based on Illness Duration

January 12, 2021

Although long-acting injectable (LAI) antipsychotics show benefit in the early stages of schizophrenia, they are mostly used later in the illness. This study assessed clinical and functional improvement with...
, , , et al
JCP
Review Article

Central and Peripheral Pharmacokinetics of Antipsychotics

July 28, 2020

Pharmacokinetics of antipsychotics are generally slower centrally than peripherally. This review examined the possible dissociation between central D2 receptor occupancy with antipsychotics and their peripheral blood concentrations.
, , , et al
JCP
Original Research

Placebo Effects in LAI Trials for Schizophrenia

December 4, 2018

Poor treatment adherence masks the true extent of placebo effects in trials of antipsychotics in schizophrenia. Can use of an injectable placebo in double-blind trials of long-acting injectable antipsychotics...
, , , et al
JCP
Original Research

Placebo Effects in the Treatment of Alzheimer's Disease

October 17, 2017

Placebo effects are a common obstacle in the search for Alzheimer's disease treatments. This analysis of data from the large CATIE-AD study investigates ways to screen out potential placebo...
, , , et al
JCP
Article

Adjusting Amisulpride Dose in Patients With Alzheimer's Disease

August 23, 2017

Few data have been published to guide antipsychotic treatment of psychosis in Alzheimer's disease. This population analysis was conducted to determine the optimal dose of amisulpride in order to...
, , , et al
JCP
Article

Predicting Recovery in Bipolar Depression

February 22, 2017

A key to improving prognosis in bipolar depression may lie in analysis of specific symptoms. This reanalysis of the STEP-BD dataset provides clues to help you determine which patients...
, , , et al
JCP
Article

Hyperprolactinemia in Older Patients With Schizophrenia

December 28, 2016

Since older patients are known to be hypersensitive to antipsychotics, are they vulnerable to developing hyperprolactinemia with these drugs? This post hoc study looked at whether the dopamine D2/3...
, , , et al
JCP
Article

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

October 26, 2016

When your patients with schizophrenia insufficiently respond to antipsychotic treatment, do you increase the dose? Do you check their plasma drug concentration? Read this CME article to find out...
, , , et al
JCP
Article

Whether to Increase or Maintain Dosage of Mirtazapine in Early Nonimprovers With Depression

April 22, 2015

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe